Analyst Ratings For BioLineRx (NASDAQ:BLRX)
Today, Roth Capital initiated coverage on BioLineRx (NASDAQ:BLRX) with a Buy with a price target of $3.00.
There are 4 buy ratings on the stock.
The current consensus rating on BioLineRx (NASDAQ:BLRX) is Buy (Score: 3.00) with a consensus target price of $2.82 per share, a potential 168.57% upside.
Some recent analyst ratings include
- 8/3/2017-Roth Capital initiated coverage with a Buy rating.
- 2/13/2017-Rodman & Renshaw initiated coverage with a Buy rating.
Recent Trading Activity for BioLineRx (NASDAQ:BLRX)
Shares of BioLineRx closed the previous trading session at 1.05 down -0.02 -1.86% with 632,930 shares trading hands.